In 1977, Thymulin was identified from the thymus. Its synthetic counterpart is Thymalin. There is speculation that Thymalin may be involved in immunological function, may have neuroprotective potential, and may regulate inflammation and pain. Several extracts from the pineal gland and thymus have been suggested to have cell life-extending properties, according to a preliminary study.
Thymalin Peptide and Vitality
At the start of the new millennium, researchers in Russia suggested that Thymalin may help normalize various basic physiological processes. Cardiovascular, immunological, and neurological systems all suggested signs of improvement following extended research. The peptide was hypothesized to maintain homeostasis and an enhanced metabolism in animal models. Arthritis symptoms, hypertension, osteoporosis, ischemic heart disease, and acute respiratory illness were all hypothesized to be significantly reduced in the research. During the experiment, the mortality rate in the Thymalin exposed models appeared to be reduced by a factor of two.
When coupled with Epithalamion, Thymalin seems to have a synergistic effect on other thymic and pineal gland isolates, reducing the death rate by a factor of four. Since the pineal gland and the thymus have been associated with cell aging, this should be no surprise.
Thymalin Peptide and the Immune System
A substantial amount of study on the immune system potential of Thymalin has indicated that the peptide may mainly change cellular immunity, influencing T-cell differentiation, levels of lymphocyte subpopulations, and natural killer (NK) cell activity. An imbalance in cellular immunity may develop into severe immunosuppression over time in a variety of physiological disorders, including diabetes, which typically increase vulnerability to infections and cancers.
Research suggests that immune correction and T-lymphocyte proliferation may reduce inflammation and slow disease progression in diabetic retinopathy animal models after Thymalin presentation. Scientists speculate that this potential might be relevant in the context of HIV-related chronic immunodeficiency and immunological dysregulation. It has been hypothesized that models of HIV may be able to recover immune system damage and boost CD4+ T-cell counts when Thymalin is present in conjunction with highly aggressive anti-retroviral compounds (HAART).
According to the research, thyroidectomy rats often endure a decrease in thymic function, weight loss, and cell proliferation decreases. Investigations suggest that these alterations may be reversed or prevented from happening altogether when Thymalin is presented. The result is believed to be a more functional organims with a stronger immune system and less likelihood of illness.
Thymalin Peptide and Cancer
Thymalin has been evaluated in combination with pulsed laser radiation in mouse studies for the aid of certain cancers. There is a moderate to high success rate when using neodymium lasers to mitigate melanoma and other precancerous and cancerous skin lesions. When it comes to stopping the spread of cancer, this method has been lauded by researchers for further study. But if Thymalin is presented at the same time as the pulsed laser, it may increase the amount of antibody-producing cells in the spleen so that the procedure can be enhanced. Theoretically, this might lead to better tumor suppression and, ultimately, a higher incidence of remission or cure.
Findings imply that laser exposure may not necessary for Thymalin to have an impact on cancer. In rat studies, concentrations of Thymalin were suggested to exert potential anti-cancer action, with tumor regression speculated in over 50% of animals and tumor development stopped in almost 80% of instances.
Combining Thymalin with plasmapheresis has also been hypothesized to be effective in the context of chronic lympholeukemia. Here, hematological compensation is theorized to be better achieved with the peptide/plasmapheresis combination than with conventional chemotherapy substances alone. The substance appeared to have a positive effect on the lymphoid system as well. To rephrase, when plasmapheresis is given with Thymalin, the blood system seems to return to equilibrium more quickly, leading to more rapid clinical and blood-based assessments of remission.
Thymalin Peptide and Psoriasis
The skin and joints might be affected by a particular inflammatory illness known as Psoriasis. Research investigations have indicated that by combining Thymalin with traditional psoriasis procedures, laboratory measurements of the illness may be improved. Laboratory assessments of Psoriasis activity suggest a strong correlation with changes in physiological condition, which is an important finding. This speculated that the effects of Thymalin on the illness state may be measured and seen.
Thymalin Peptide and Tuberculosis
Animal research models in the study received either regular antibiotic compounds or antibiotic procedures in conjunction with Thymalin for their severe progressing pulmonary TB. The findings implied that the cure rates appeared to be much higher in the Thymalin groups than in the antibiotic-only groups. There was an almost 95% cure rate when the Thymalin/antibiotic approach was tailored to body requirements, which appeared promising. This is significant because TB may potentially develop resistance to both established and experimental antibiotic regimens, which may include anywhere from one to four different antibacterial compounds.
Research models with severe TB may exhibit a larger depression of cellular immunity, as evaluated by T-cell counts. T-cells are both less abundant and less competent in blast transformation. Cellular immunity declines dramatically even more when coupled with an immunosuppressive illness, such as diabetes. Research indicates that Thymalin may potentially support the immune system in this situation so the organism can fight off infections more efficiently.
Thymalin Peptide and the Kidneys
Presentation of Thymalin may exert impact in cases of chronic glomerulonephritis, an inflammatory kidney condition, as suggested by research. Research models in a Russian clinical trial who were given Thymalin seemed to have better kidney function and lower inflammatory markers in their blood. Additionally, they suggested improvements in immunologic disease parameters, which might mean less kidney damage overall, which would mean remission or, at the very least, a postponement of dialysis or transplant. Clinical study is severely limited and the peptide is not approved for human use.
Buy Thymalin peptide if you are a researcher interested in further studying this peptide.
References
[i] V. K. Khavinson and V. G. Morozov, “Peptides of pineal gland and thymus prolong human life,” Neuro Endocrinol. Lett., vol. 24, no. 3–4, pp. 233–240, Aug. 2003
[ii] V. K. Khavinson and V. G. Morozov, “[Geroprotective effect of thymalin and epithalamin],” Adv. Gerontol. Uspekhi Gerontol., vol. 10, pp. 74–84, 2002.
[iii] N. S. Lin’kova, V. O. Poliakova, I. M. Kvetnoĭ, A. V. Trofimov, and N. N. Sevost’ianova, “[Characteristics of the pineal gland and thymus relationship in aging],” Adv. Gerontol. Uspekhi Gerontol., vol. 24, no. 1, pp. 38–42, 2011.
[iv] J. Bach, M. Bardenne, J. Pleau, and J. Rosa, “Biochemical characterisation of a serum thymic factor,” Nature, vol. 266, no. 5597, pp. 55–57, Mar. 1977
[v] A. M. Reznichenko, V. P. Fesenko, D. V. Shestopalov, and P. A. Tatarchuk, “[Changes in cell immunity indexes under the influence of thymalin, thyroxine and fibronectin in patients with hyperplastic diseases of thyroid gland before and after the surgery],” Klin. Khir., no. 12, pp. 31– 33, Dec. 2001
[vi] H. D. Zhaboiedov, N. H. Bychkova, R. L. Skrypnik, and M. V. Sydorova, “[Evaluation of cellular and humoral immunity and individual sensitivity of T-lymphocytes to immunocorrectors in patients with diabetic retinopathy],” Lik. Sprava, no. 1, pp. 53–56, Feb. 2001
[vii] E. Montomoli, S. Piccirella, B. Khadang, E. Mennitto, R. Camerini, and A. De Rosa, “Current adjuvants and new perspectives in vaccine formulation,” Expert Rev. Vaccines, vol. 10, no. 7, pp. 1053–1061, Jul. 2011.
[viii] I. I. Hrinevych, H. D. Bendiuh, N. M. Khranovs’ka, I. M. Bilokin’, and O. M. Ostapenko, “[Effect of thyroxin and thymalin on proliferation and apoptosis of thymocytes in rats after thyroidectomy],” Fiziolohichnyi Zhurnal Kiev Ukr. 1994, vol. 50, no. 3, pp. 39–43, 2004.
[ix] A. P. Kozlov and K. G. Moskalik, “Pulsed laser radiation therapy of skin tumors,” Cancer, vol. 46, no. 10, pp. 2172–2178, Nov. 1980.
[x] R. I. Wagner, A. P. Kozlov, and K. G. Moskalik, “Laser radiation therapy of skin melanoma,” Strahlentherapie, vol. 157, no. 10, pp. 670–672, Oct. 1981
